This article was originally published in The Gray Sheet
Executive SummaryMcGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.